NAMPT and neoplasm: ATG-019, which inhibits both PAK4 and NAMPT, has shown improved efficacy in combination with anti-PD-1 therapy in murine tumor models compared to anti-PD-1 alone, representing a novel treatment strategy for advanced solid tumors and non-Hodgkin’s lymphoma (107, 108).